For the first time in the history of the Controlled Substances Act, a single substance has been divided into two separate federal classifications. Acting Attorney General Todd Blanche's April 22, 2026 order reclassified state-licensed medical marijuana from Schedule I to Schedule III - effective upon publication in the Federal Register on April 28 - while recreational marijuana remains a Schedule I controlled substance. The split creates an unprecedented compliance environment that dispensary operators, multi-state operators, and cannabis lawyers are still working to parse.
What the Order Actually Does - and What It Doesn't
The statutory language matters here. Schedule III, under 21 U.S.C. § 812(b)(3), applies to substances with a lower abuse potential than Schedule I or II drugs, a currently accepted medical use in the United States, and a risk profile limited to moderate or low physical dependence, or high psychological dependence. That puts medical marijuana in the same federal category as Ketamine and Testosterone - substances that are controlled, regulated, and legal to prescribe, but not prohibited outright.
The catch is that the AAG's order ties Schedule III status directly to state medical marijuana licensure. If a business holds a state-issued medical marijuana license, the marijuana it handles now falls under Schedule III federally. Recreational marijuana - sold under adult-use licenses - does not. That sounds like a clean line on paper, but in practice, many operators run dual-licensed facilities serving both medical patients and adult-use consumers from the same inventory, the same POS system, and often the same budroom floor. How federal compliance protocols will treat co-located medical and adult-use product batches is not answered by the order.
There is also the question of what "state-licensed medical marijuana businesses" actually means. The order does not define the term with precision. Does it encompass vertically integrated operators with cultivation, processing, and retail under a single medical license umbrella? What about wholesale suppliers whose product flows through licensed medical dispensaries but who hold a different license category at the state level? These are not hypothetical edge cases - they describe the operational structure of a significant portion of the licensed cannabis industry.
The DEA Hearings Are Still Ahead, and That Matters
The AAG's order did not conclude the federal rescheduling process. The DEA's administrative reclassification hearings are scheduled to begin June 29, 2026, and those proceedings will carry their own evidentiary record, legal arguments, and potential modifications. The DOJ action and the DEA hearing process are related but distinct - and the outcome of the DEA process could alter, confirm, or complicate what Blanche's order set in motion.
Former federal prosecutors and IRS lawyers advising cannabis businesses have flagged the DEA's expedited registration process as an area requiring particular caution. The concern is not abstract. Federal registration under the DEA carries broad statutory obligations, and any operator who moves quickly to obtain DEA registration without fully understanding the conditions attached - reporting requirements, inspection rights, recordkeeping obligations - could find themselves subject to a level of federal scrutiny that state-licensed cannabis businesses have not historically experienced. The DEA's authority over Schedule III registrants is not limited to paperwork. It includes the power to conduct inspections, require detailed transaction records, and impose administrative sanctions.
To put it plainly: securing a DEA registration is not the same as obtaining a state cannabis license. The compliance architecture is different, the enforcement posture is different, and the federal agency involved has a longer institutional memory than most state cannabis regulators.
280E Relief and the Tax Question
One of the most immediate practical implications of Schedule III reclassification - at least for the medical side of the business - is the potential unwinding of 280E exposure. Section 280E of the Internal Revenue Code disallows federal tax deductions for businesses trafficking in Schedule I or Schedule II controlled substances. If medical cannabis is now Schedule III, the argument follows that medical cannabis operators are no longer subject to 280E's harsh restrictions on ordinary business deductions - rent, payroll, marketing, utilities - that non-cannabis retailers take for granted.
That is a meaningful shift for operators who have been paying effective federal tax rates far exceeding those of comparable retail businesses precisely because of 280E. But the caveat applies again: recreational marijuana remains Schedule I, which means dual-license operators will need meticulous accounting separation between their medical and adult-use business activities if they intend to claim relief on the medical side. Comingled cost-of-goods accounting, shared overhead allocations, and blended inventory records - common in operations that grew up under a single 280E compliance posture - will require restructuring. The IRS has not yet issued formal guidance on how it will treat this bifurcated structure, and operators should treat any 280E relief claims as legally contested until that guidance exists.
Epidiolex, FDA-Approved Products, and an Unresolved Status
The rescheduling order also extends Schedule III classification to FDA-approved products containing non-synthetic marijuana - a category with meaningful implications for pharmaceutical-adjacent cannabis business models. What remains genuinely unresolved is the status of Epidiolex, the CBD-derived epilepsy medication that was first approved as Schedule V in 2018 and then removed entirely from the CSA schedule in 2020. The April 2026 order does not appear to resolve where Epidiolex sits in the new framework, leaving manufacturers, pharmacies, and distributors of that product without clear federal guidance.
This is not a peripheral issue for the B2B cannabis supply chain. The boundary between state-licensed cannabis products and FDA-regulated pharmaceutical products has always been contested, and rescheduling creates new pressure points at that boundary. Any supplier, processor, or retailer whose product line includes or approaches FDA-regulated cannabinoid formulations should be tracking this question closely - and not assuming that the DEA hearings will resolve it quickly.
The broader picture here is one of deliberate, incremental federal movement - not a sudden opening. Operators who treat this reclassification as a green light for rapid federal integration are reading the moment incorrectly. What it actually signals is a regulatory process in motion, with consequential decisions still pending and compliance obligations that are meaningfully different depending on which license type, which product category, and which federal agency a business is dealing with on any given day.